Dr. Drug Rep tells all

We've seen the numbers and read the surveys. Now, we can hear the story straight from the horse's, er, doctor's mouth. An M.D. and former speaker-on-behalf-of-a-drug tells his story in the New York Times Magazine, and it's an illuminating, behind-the-scenes look at how Dr. Daniel Carlat (photo) became Dr. Drug Rep.

First, the reel-in: a flattering call from Wyeth, which wanted Dr. Carlat to spread the (good) word about Effexor XR, and an expense-paid trip to Manhattan for speakers' education. Second, the spiel: Soon, Dr. Carlat was delivering his talk all over the Boston area. Third, the prick of conscience: Lo and behold, Dr. Carlat realizes he's been spinning the data in Wyeth's favor. You'll have to read the article for the rest.

One interesting tidbit in the article was the fact that drug makers don't have access to doctors' prescribing histories without the help of the American Medical Association. Pharmacy data typically IDs the prescriber by DEA number. Only by buying a list from the AMA can data-mining companies link the prescriptions to the doctors' names--and then resell the info to pharma companies.

- check out the article from The New York Times

Related Articles:
Top Lilly exec plays secret sales agent. Report
No freebies? No entry for pharma reps. Report
Wyeth gets OK to use Effexor XR for panic disorder. Report
Hospital to ban pharma rep freebies. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.